Evaluation of the Expression Pattern of rAAV2/1, 2/5, 2/7, 2/8, and 2/9 Serotypes With Different Promoters in the Mouse Visual Cortex

被引:36
|
作者
Scheyltjens, Isabelle [1 ]
Laramee, Marie-Eve [1 ]
Van den Haute, Chris [2 ,3 ]
Gijsbers, Rik [3 ,4 ]
Debyser, Zeger [4 ]
Baekelandt, Veerle [2 ]
Vreysen, Samme [1 ]
Arckens, Lutgarde [1 ]
机构
[1] Katholieke Univ Leuven, Lab Neuroplast & Neuroprote, Dept Biol, B-3000 Leuven, Belgium
[2] Katholieke Univ Leuven, Lab Neurobiol & Gene Therapy, Dept Neurosci, B-3000 Leuven, Belgium
[3] Katholieke Univ Leuven, Leuven Viral Vector Core, B-3000 Leuven, Belgium
[4] Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, B-3000 Leuven, Belgium
关键词
viral vector; GABA; CMV; CaMKII alpha; connectivity; optogenetic; ADENOASSOCIATED VIRUS TYPE-2; NONHUMAN PRIMATE BRAIN; CENTRAL-NERVOUS-SYSTEM; VIRAL VECTORS; GENE-THERAPY; ARCHITECTONIC PARCELLATION; NEUROFILAMENT PROTEIN; TRANSGENE EXPRESSION; NIGROSTRIATAL SYSTEM; CORTICAL-NEURONS;
D O I
10.1002/cne.23819
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
This study compared the expression pattern, laminar distribution, and cell specificity of several rAAV serotypes (2/1, 2/5, 2/7, 2/8, and 2/9) injected in the primary visual cortex (V1) of adult C57Bl/6J mice. In order to obtain specific expression in certain neuron subtypes, different promoter sequences were evaluated for excitatory cell specificity: a universal cytomegalovirus (CMV) promoter, and two versions of the excitatory neuron-specific Ca2+/calmodulin-dependent kinase subunit alpha (CaMKII alpha) promoter, CaMKII alpha 0.4 and CaMKII alpha 1.3. The spatial distribution as well as the cell type specificity was immunohistochemically verified. Depending on the rAAV serotype used, the transduced volume expressing reporter protein differed substantially (rAAV2/5 >> 2/7 approximate to 2/9 approximate to 2/8 >> 2/1). Excitatory neuron-specific targeting was promoter dependent, with a surprising difference between the 1.3 kb and 0.4 kb CaMKII alpha promoters. While CaMKII alpha 1.3 and CMV carrying vectors were comparable, with 78% of the transduced neurons being excitatory for CMV and 82% for CaMKII alpha 1.3, the shorter CaMKII alpha 0.4 version resulted in 95% excitatory specificity. This study therefore puts forward the CaMKII alpha 0.4 promoter as the best choice to target excitatory neurons with rAAVs. Together, these results can be used as an aid to select the most optimal vector system to deliver transgenes into specific rodent neocortical circuits, allowing further elucidation of their functions. (C) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:2019 / 2042
页数:24
相关论文
共 50 条
  • [1] Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat
    Reimsnider, Sharon
    Manfredsson, Fredric P.
    Muzyczka, Nicholas
    Mandel, Ronald J.
    MOLECULAR THERAPY, 2007, 15 (08) : 1504 - 1511
  • [2] rAAV2/8 and rAAV2/9 efficiently transduce the mouse enteric nervous system after postnatal i.v. injection
    Buckinx, R.
    Van Remoortel, S.
    Gijsbers, R.
    Debyser, Z.
    Waddington, S.
    Timmermans, J. -P.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2015, 27 : 47 - 47
  • [3] Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9
    A Van der Perren
    J Toelen
    M Carlon
    C Van den Haute
    F Coun
    B Heeman
    V Reumers
    L H Vandenberghe
    J M Wilson
    Z Debyser
    V Baekelandt
    Gene Therapy, 2011, 18 : 517 - 527
  • [4] Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9
    Van der Perren, A.
    Toelen, J.
    Carlon, M.
    Van den Haute, C.
    Coun, F.
    Heeman, B.
    Reumers, V.
    Vandenberghe, L. H.
    Wilson, J. M.
    Debyser, Z.
    Baekelandt, V.
    GENE THERAPY, 2011, 18 (05) : 517 - 527
  • [5] Administration of rAAV2/8 and rAAV2/1 Vectors Mediates Sustained Correction of a Canine Model of Glycogen Storage Disease Type Ia
    Correia, Catherine
    Weinstein, David
    Fiske, Laurie
    Verstegen, John
    Specht, Andrew
    Struck, Maggie
    Ramirez, Harvey
    Onclin-Verstegen, Karine
    Porvasnik, Stacy
    Chou, Janice
    Byrne, Barry
    Mah, Cathryn
    MOLECULAR THERAPY, 2009, 17 : S66 - S66
  • [6] rAAV2/5 gene-targeting to rods: dose-dependent efficiency and complications associated with different promoters
    Beltran, W. A.
    Boye, S. L.
    Boye, S. E.
    Chiodo, V. A.
    Lewin, A. S.
    Hauswirth, W. W.
    Aguirre, G. D.
    GENE THERAPY, 2010, 17 (09) : 1162 - 1174
  • [7] rAAV2/5 gene-targeting to rods:dose-dependent efficiency and complications associated with different promoters
    W A Beltran
    S L Boye
    S E Boye
    V A Chiodo
    A S Lewin
    W W Hauswirth
    G D Aguirre
    Gene Therapy, 2010, 17 : 1162 - 1174
  • [8] Epirubicin Potentiates rAAV2/5-Mediated TRAIL Expression in Fibroblast-Like Synoviocytes and Augments the Anti-Arthritis Effects of rAAV2/5-TRAIL
    Shi, Juan
    You, Xin
    Zheng, Dexian
    MOLECULAR THERAPY, 2012, 20 : S102 - S102
  • [9] Differential transgene expression profiles from rAAV2/1 vectors using the tetON and CMV promoters in the rat brain
    Bockstael, Olivier
    Chtarto, Abdelwahed
    Wakkinen, Janika
    Yang, Xin
    Melas, Catherine
    Levivier, Marc
    Brotchi, Jacques
    Tenenbaum, Liliane
    HUMAN GENE THERAPY, 2008, 19 (10) : 1198 - 1199
  • [10] Life-long gene expression in mouse airways after rAAV2/5 based gene therapy
    Carlon, Marianne
    Vidovic, Dragana
    Dooley, James
    Jimenez, Ana Quiles
    Van den Haute, Chris
    Baekelandt, Veerle
    Liston, Adrian
    Gijsbers, Rik
    Debyser, Zeger
    HUMAN GENE THERAPY, 2014, 25 (11) : A110 - A110